CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $834.42 million. The enterprise value is $548.57 million.
| Market Cap | 834.42M |
| Enterprise Value | 548.57M |
Important Dates
The next estimated earnings date is Thursday, August 15, 2024, before market open.
| Earnings Date | Aug 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 224.31 million shares outstanding. The number of shares has increased by 17.68% in one year.
| Shares Outstanding | 224.31M |
| Shares Change (YoY) | +17.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.27% |
| Owned by Institutions (%) | 21.68% |
| Float | 122.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.17 |
| PS Ratio | 13.01 |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.25 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -143.76 |
Financial Efficiency
Return on equity (ROE) is -49.40% and return on invested capital (ROIC) is -58.90%.
| Return on Equity (ROE) | -49.40% |
| Return on Assets (ROA) | -33.90% |
| Return on Capital (ROIC) | -58.90% |
| Revenue Per Employee | $54,721 |
| Profits Per Employee | -$253,470 |
| Employee Count | 1,172 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 5.72 |
Taxes
In the past 12 months, CureVac has paid $936,851 in taxes.
| Income Tax | 936,851 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.29% in the last 52 weeks. The beta is 2.64, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.64 |
| 52-Week Price Change | -56.29% |
| 50-Day Moving Average | 3.65 |
| 200-Day Moving Average | 3.95 |
| Relative Strength Index (RSI) | 55.99 |
| Average Volume (20 Days) | 1,262,251 |
Short Selling Information
The latest short interest is 7.49 million, so 3.34% of the outstanding shares have been sold short.
| Short Interest | 7.49M |
| Short Previous Month | 6.10M |
| Short % of Shares Out | 3.34% |
| Short % of Float | 6.11% |
| Short Ratio (days to cover) | 5.70 |
Income Statement
In the last 12 months, CureVac had revenue of $64.13 million and -$297.07 million in losses. Loss per share was -$1.32.
| Revenue | 64.13M |
| Gross Profit | -93.81M |
| Operating Income | -311.74M |
| Pretax Income | -295.75M |
| Net Income | -297.07M |
| EBITDA | -269.39M |
| EBIT | -293.71M |
| Loss Per Share | -$1.32 |
Balance Sheet
The company has $329.97 million in cash and $44.12 million in debt, giving a net cash position of $285.85 million or $1.27 per share.
| Cash & Cash Equivalents | 329.97M |
| Total Debt | 44.12M |
| Net Cash | 285.85M |
| Net Cash Per Share | $1.27 |
| Equity (Book Value) | 485.16M |
| Book Value Per Share | 2.16 |
| Working Capital | 227.92M |
Cash Flow
In the last 12 months, operating cash flow was -$287.52 million and capital expenditures -$48.16 million, giving a free cash flow of -$335.68 million.
| Operating Cash Flow | -287.52M |
| Capital Expenditures | -48.16M |
| Free Cash Flow | -335.68M |
| FCF Per Share | -$1.50 |
Margins
Gross margin is -146.28%, with operating and profit margins of -486.09% and -463.21%.
| Gross Margin | -146.28% |
| Operating Margin | -486.09% |
| Pretax Margin | -461.16% |
| Profit Margin | -463.21% |
| EBITDA Margin | -420.05% |
| EBIT Margin | -457.97% |
| FCF Margin | -523.42% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.68% |
| Shareholder Yield | -17.68% |
| Earnings Yield | -35.60% |
| FCF Yield | -40.23% |
Analyst Forecast
The average price target for CureVac is $10.00, which is 168.82% higher than the current price. The consensus rating is "Hold".
| Price Target | $10.00 |
| Price Target Difference | 168.82% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 18.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -2.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.27 |
| Piotroski F-Score | 4 |